Utama › Kanser Kolorektal › Illinois › Arlington Heights
Kajian klinikal Kanser Kolorektal di Arlington Heights, IL
12 kajian untuk Kanser Kolorektal sedang mencari peserta di lokasi dalam dan sekitar Arlington Heights (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Family Communications After Genetic Testing
Mengambil pesertaSukarelawan sihat dialu-alukan
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauh
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauh
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Mengambil pesertaFasa 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Mengambil pesertaFasa 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Mengambil pesertaFasa 3
- Illinois Cancer Specialists, Arlington Heights
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Mengambil pesertaFasa 3
- Alexian Brothers Medical Center, Elk Grove Village · 6 mi jauh
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Mengambil pesertaFasa 1
- Illinois Cancer Specialists, Arlington Heights
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Mengambil pesertaFasa 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Mengambil pesertaFasa 2
- Illinois Cancer Specialists, Arlington Heights
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauh
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Mengambil pesertaKajian pemerhatian
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauh
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Gastroenterology and Internal Medicine Specialists, Lake Barrington · 12 mi jauh
Kajian Kanser Kolorektal di bandar lain
- Houston, TX102 kajian
- New York City, NY78 kajian
- Nashville, TN69 kajian
- Boston, MA63 kajian
- Los Angeles, CA59 kajian
- Arlington, VA52 kajian
- St. Louis, MO50 kajian
- San Antonio, TX46 kajian
- Philadelphia, PA44 kajian
- Grand Rapids, MI40 kajian
- Baldwin Park, CA37 kajian
- Chicago, IL34 kajian
Kajian lain di Arlington Heights
- Kanser Paru-paru Bukan Sel Kecil12 kajian
- Kanser Paru-paru9 kajian
- Kanser Payudara7 kajian
- Kegagalan Jantung7 kajian
- Kanser Metastatik6 kajian
- Kolitis Ulseratif6 kajian
- Kanser Kolon6 kajian
- Kanser Ovari5 kajian
- Obesiti5 kajian
- Berat Badan Berlebihan5 kajian
- Kanser Prostat3 kajian
- Keadaan Kulit3 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.